Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: An exploratory analysis of 851 cases

Oncotarget

Volumn 7, Issue 35, 2016, Pages 57290-57300

  Wang, Yun ^a   Wang, Zhi Qiang ^a   Wang, Feng Hua ^a   Lei, Xue Fen ^b   Yan, Shu Mei ^a   Wang, De Shen ^a   Zhang, Fei ^a   Xu, Rui Hua ^a   Wang, Ling Yun ^c   Li, Yu Hong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Colorectal cancer; High density lipoprotein cholesterol; Prognosis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CA 19-9 ANTIGEN; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXALIPLATIN; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; APOA1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; BLOOD; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL, HDL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84984910976     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10145     Document Type: Article

References (28)

1. Dai Z, Zheng RS, Zou XN, Zhang SW, Zeng HM, Li N and Chen WQ. [Analysis and prediction of colorectal cancer incidence trend in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2012; 46:598-603.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016.
3. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S and Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. GASTROENTEROLOGY. 2003; 124:544-560.
4. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M and Mori M. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J CLIN ONCOL. 2011; 29:1547-1555.
5. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, Tedde A, Desogus A and Muntoni S. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2009; 19:218-225.
6. Munir R, Usman H, Hasnain S, Smans K, Kalbacher H and Zaidi N. Atypical plasma lipid profile in cancer patients: cause or consequence? BIOCHIMIE. 2014; 102:9-18.
7. Vilchez JA, Martinez-Ruiz A, Sancho-Rodriguez N, Martinez-Hernandez P and Noguera-Velasco JA. The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review. EUR J CLIN INVEST. 2014; 44:103-114.
8. Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A and Raptis S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol. 1992; 30:412-416.
9. Melichar B, Kalabova H, Krcmova L, Kasparova M, Malirova E, Melicharova K, Pecka M, Hyspler R and Solichova D. Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. ANTICANCER RES. 2009; 29:4813-4820.
10. Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM and McCormick SP. Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLOS ONE. 2016; 11:e148049.
11. Basani S and Garg A. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. J CLIN LIPIDOL. 2015; 9:832-836.
12. Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG and Karayiannacos PE. Influence of 5-fluorouracil on serum lipids. ACTA ONCOL. 1995; 34:253-256.
13. Chi PD, Liu W, Chen H, Zhang JP, Lin Y, Zheng X, Liu W and Dai S. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLOS ONE. 2014; 9:e91080.
14. Tamura T, Inagawa S, Hisakura K, Enomoto T and Ohkohchi N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol. 2012; 27:1635-1640.
15. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K and Remaley AT. High-density lipoprotein and prostate cancer: an overview. J EPIDEMIOL. 2013; 23:313-319.
16. Jafri H, Alsheikh-Ali AA and Karas RH. Baseline and ontreatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J AM COLL CARDIOL. 2010; 55:2846-2854.
17. Luo XL, Zhong GZ, Hu LY, Chen J, Liang Y, Chen QY, Liu Q, Rao HL, Chen KL and Cai QQ. Serum apolipoprotein A-I is a novel prognostic indicator for nonmetastatic nasopharyngeal carcinoma. ONCOTARGET. 2015; 6:44037-48. doi: 10.18632/oncotarget.5823.
18. Jiang R, Yang ZH, Luo DH, Guo L, Sun R, Chen QY, Huang PY, Qiu F, Zou X, Cao KJ, Mai HQ, Guo X, Qian CN, Hong MH and Chen MY. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. MED ONCOL. 2014; 31:80.
19. Cheng T, Dai X, Zhou DL, Lv Y and Miao LY. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced nonsmall cell lung cancer. MED ONCOL. 2015; 32:407.
20. Fiorenza AM, Branchi A and Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000; 30:141-145.
21. Zamanian-Daryoush M and DiDonato JA. Apolipoprotein A-I and Cancer. Front Pharmacol. 2015; 6:265.
22. Tan JT, Ng MK and Bursill CA. The role of highdensity lipoproteins in the regulation of angiogenesis. CARDIOVASC RES. 2015; 106:184-193.
23. Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA and Hazen SL. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J BIOL CHEM. 2013; 288:21237-21252.
24. Sag D, Cekic C, Wu R, Linden J and Hedrick CC. The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. NAT COMMUN. 2015; 6:6354.
25. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman AM, Reddy ST and Farias-Eisner R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. MOL CANCER THER. 2012; 11:1311-1319.
26. Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman AM, Reddy ST and Farias-Eisner R. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1alpha in human ovarian cancer cell lines and a mouse ovarian cancer model. J PHARMACOL EXP THER. 2012; 342:255-262.
27. Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL, Marchetti A, Sacco R, Mucilli F, Malatesta S, Guetti L and Vitale L, et al. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. LUNG CANCER. 2009; 66:365-371.
28. Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L and Gamucci T, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. ONCOTARGET. 2015; 6:42773-80. doi: 10.18632/oncotarget.6001.